The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
July 15, 2024
View Complete Issue         Table of Contents 2019 
Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia
July 15, 2024 (Issue: 5076)
The FDA has approved pilocarpine 0.4% preservativefree ophthalmic solution (Qlosi – Orasis) for treatment of presbyopia in adults. Pilocarpine 1.25% ophthalmic solution (Vuity) was approved in 2021 for the same indication. Pilocarpine 1%, 2%,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia
Article code: 5076a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.